Idarucizumab: the antidote for reversal of dabigatran
JW Eikelboom, DJ Quinlan, J van Ryn, JI Weitz - Circulation, 2015 - Am Heart Assoc
Four non–vitamin K antagonist oral anticoagulants (NOACs), including the direct thrombin
inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban …
inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban …
Monitoring and reversal of direct oral anticoagulants
Although the direct oral anticoagulants (DOACs) do not require routine monitoring and
reduce bleeding compared with warfarin, there are special circumstances in which …
reduce bleeding compared with warfarin, there are special circumstances in which …
Reversal strategies for intracranial hemorrhage related to direct oral anticoagulant medications
A Dabi, AP Koutrouvelis - Critical Care Research and Practice, 2018 - Wiley Online Library
Direct oral anticoagulants (DOACs) are a new class of anticoagulants that directly inhibit
either thrombin or factor Xa in the coagulation cascade. They are being increasingly used …
either thrombin or factor Xa in the coagulation cascade. They are being increasingly used …
A new option for reversing the anticoagulant effect of factor Xa inhibitors: andexanet alfa (ANDEXXA)
KC Rogers, SW Finks - The American Journal of Medicine, 2019 - Elsevier
The use of direct oral anticoagulants over traditional warfarin has increased in the United
States over the past 10 years because of advantages such as ease of use, predictable …
States over the past 10 years because of advantages such as ease of use, predictable …
Old and new anticoagulant drugs: a minireview
PM Mannucci, M Franchini - Annals of medicine, 2011 - Taylor & Francis
The limits of traditional anticoagulants, such as heparin and warfarin, have prompted the
search for new agents for prophylaxis and treatment of arterial and venous …
search for new agents for prophylaxis and treatment of arterial and venous …
Antidotes for reversal of direct oral anticoagulants
PP Dobesh, SH Bhatt, TC Trujillo, K Glaubius - Pharmacology & …, 2019 - Elsevier
The main advantage of the direct oral anticoagulants over vitamin K antagonists is reduced
rates of major bleeding, especially intracranial hemorrhage. While use of different clotting …
rates of major bleeding, especially intracranial hemorrhage. While use of different clotting …
Direct oral anticoagulants: a guide for daily practice
P Fontana, H Robert-Ebadi, H Bounameaux… - Swiss medical …, 2016 - smw.ch
In recent years, small oral compounds that specifically block activated coagulation factor X
(FXa) or thrombin (FIIa) have become alternatives to the anticoagulants that had been used …
(FXa) or thrombin (FIIa) have become alternatives to the anticoagulants that had been used …
Measurement and reversal of the direct oral anticoagulants
BT Samuelson, A Cuker - Blood reviews, 2017 - Elsevier
Direct oral anticoagulants (DOACs) offer noninferior efficacy and improved safety compared
to vitamin K antagonists (VKAs) for the prevention and treatment of venous …
to vitamin K antagonists (VKAs) for the prevention and treatment of venous …
[HTML][HTML] Management of bleeding in patients receiving direct oral anticoagulants
DA Garcia, M Crowther, ME Moreira - U: UpToDate, Post TW ur. UpToDate …, 2018 - medilib.ir
INTRODUCTION—The use of any anticoagulant is associated with an increased risk of
bleeding, and bleeding complications can be life-threatening. Management of bleeding in …
bleeding, and bleeding complications can be life-threatening. Management of bleeding in …
Direct oral anticoagulants: new drugs and new concepts
JH Levy, AC Spyropoulos, CM Samama… - JACC: Cardiovascular …, 2014 - jacc.org
Direct oral anticoagulants (DOACs) are approved for multiple thromboembolic disorders and
provide advantages over existing agents. As with all anticoagulants, management protocols …
provide advantages over existing agents. As with all anticoagulants, management protocols …